Condition: Eating Disorders · Binge Eating · Purging (Eating Disorders) · Sponsor: Children's Mercy Hospital Kansas City
Using a randomized, placebo-controlled, crossover study, this study will evaluate functional magnetic resonance imaging (fMRI) as a pharmacodynamic biomarker of opioid antagonism in adolescents with eating disorders. The hypothesis is that fMRI will be able to detect acute reward pathway modulation by naltrexone (an opioid antagonist) in pre-defined regions of interest (anterior cingulate cortex, nucleus accumbens, dorsolateral prefrontal cortex).
This description comes directly from the study's public registry record.
Mariah L Brewe, BA · (816) 916-3409 · mbrewe@cmh.edu
Stephani Stancil, PhD · slstancil@cmh.edu
Always discuss trial participation with your own doctor first.
| Children's Mercy Research Institute | Kansas City, Missouri, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05509257